MAZE
insider transactionsMaze Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 30d
-54.6K
0 buy · 54.6K sell
Net value · 30d
-$1.4M
$0 in · $1.4M out
Sentiment · 30d
Net selling
0% buying · 100% selling
Open-market trades · 30d
6
0 buy · 54.6K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
18.0K sh
Own New
-
Grant·A
Director
$0
18.0K sh
Own New
-
Grant·A
Director
$0
18.0K sh
Own New
-
Grant·A
Director
$0
18.0K sh
Own New
-
Grant·A
Director
$0
18.0K sh
Own New
-
Grant·A
Director
$0
18.0K sh
Own New
-
Sell·S
Jason V Coloma KEY
Chief Executive Officer · 10b5-1
$14.5K
553 sh · $26.24
Own -2%
-
Sell·S
Jason V Coloma KEY
Chief Executive Officer · 10b5-1
$159.5K
6.1K sh · $26.20
Own -2%
-
Exercise·M
Harold Bernstein KEY
President, R&D & CMO · 10b5-1
$0
14.9K sh
Own +8%
-
Sell·S
Harold Bernstein KEY
President, R&D & CMO · 10b5-1
$42.2K
1.6K sh · $26.36
Own -100%
-
Sell·S
Harold Bernstein KEY
President, R&D & CMO · 10b5-1
$338.9K
13.3K sh · $25.57
Own -89%
-
Exercise·M
Harold Bernstein KEY
President, R&D & CMO · 10b5-1
$154.8K
14.9K sh · $10.42
Own New
-
Exercise·M
CSBO · 10b5-1
$0
7.5K sh
Own +26%
-
Sell·S
CSBO · 10b5-1
$197.6K
7.5K sh · $26.34
Own -23%
-
Exercise·M
CSBO · 10b5-1
$78.2K
7.5K sh · $10.42
Own +30%
-
Sell·S
Jason V Coloma KEY
Chief Executive Officer · 10b5-1
$665.5K
25.6K sh · $26.02
Own -7%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 8, 2026 | Daniel K Spiegelman | Grant A | 18.0K | $0 |
| Jun 8, 2026 | Richard H Scheller | Grant A | 18.0K | $0 |
| Jun 8, 2026 | Jonathan E Lim | Grant A | 18.0K | $0 |
| Jun 8, 2026 | Herve Hoppenot | Grant A | 18.0K | $0 |
| Jun 8, 2026 | Charles J Homcy | Grant A | 18.0K | $0 |
| Jun 8, 2026 | Nancy C Andrews | Grant A | 18.0K | $0 |
| Jun 1, 2026 | Jason V Coloma KEY 10b5-1 | Sell S | 553 | $14.5K |
| Jun 1, 2026 | Jason V Coloma KEY 10b5-1 | Sell S | 6.1K | $159.5K |
| Jun 1, 2026 | Harold Bernstein KEY 10b5-1 | Exercise M | 14.9K | $0 |
| Jun 1, 2026 | Harold Bernstein KEY 10b5-1 | Sell S | 1.6K | $42.2K |
| Jun 1, 2026 | Harold Bernstein KEY 10b5-1 | Sell S | 13.3K | $338.9K |
| Jun 1, 2026 | Harold Bernstein KEY 10b5-1 | Exercise M | 14.9K | $154.8K |
| May 29, 2026 | Atul Dandekar 10b5-1 | Exercise M | 7.5K | $0 |
| May 29, 2026 | Atul Dandekar 10b5-1 | Sell S | 7.5K | $197.6K |
| May 29, 2026 | Atul Dandekar 10b5-1 | Exercise M | 7.5K | $78.2K |
| May 26, 2026 | Jason V Coloma KEY 10b5-1 | Sell S | 25.6K | $665.5K |
About MAZE insider trading
This page tracks insider transactions for Maze Therapeutics, Inc. (MAZE) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.